Blood test shows promise for early ovarian cancer detection with 91% accuracy

Early detection could improve outcomes for approximately 7,500 women diagnosed with ovarian cancer annually in the UK.

Each year, thousands of women in the UK receive an ovarian cancer diagnosis too late for treatment to work at its best — not because medicine has failed to care, but because the disease has long resisted early discovery. Researchers at the universities of Manchester and Colorado, working with diagnostics company AOA Dx, have now developed a blood test that reads the molecular fingerprints cancer cells leave in the bloodstream, using machine learning to detect patterns no human eye could reliably discern. Achieving 91% accuracy in early-stage cases, the test represents a quiet but profound shif

Blood test shows promise for early ovarian cancer detection with 91% accuracy

Cobertura Relacionada

Receba o Register no seu e-mail